More specifically, GLP-1R expression has been identified in several hypothalamic and basal forebrain regions, including the paraventricular nucleus, supraoptic nucleus, infundibular nucleus/arcuate nucleus, lateral hypothalamic area, and nuclei of the basal forebrain, where they exhibit relatively well-defined regional expression patterns (43, 44)
This is a critical methodological confounder that has been inflating the perceived muscle wasting signal in large clinical trials
Advances in drug delivery technology are enabling the development of effective oral GLP-1 therapies, such as oral semaglutide, expanding the potential patient base
The products offered on this website are furnished for in-vitro studies only
In other words, BPC 157 may support the conditions that allow hypertrophy training to continue, but it should not be framed as a direct muscle-growth peptide